Pursue gender-affirming care vs. living without medical treatment
If you act
Pursue gender-affirming care (hormones and/or surgery)
3.0%
If you don't
Live without gender-affirming medical treatment
40%
Percentage who later regret each choice. Bars and full ledger render below.
Health
Last reviewed 2026-05-04
Evidence quality 4.5/5
Eight-dimension review score against the
quality rubric
. Each dimension scored 1–5.
D1 Source verification
4/5
D2 Source authority & independence
5/5
D3 Regret-rate accuracy
3/5
D4 Source comparability
4/5
D5 Gilovich pattern
5/5
D6 Prose quality
5/5
D7 Caveat completeness
5/5
D8 Sample quality
5/5
Average4.5/5
Proxy data — no direct regret survey exists for this decision. Rates are derived from satisfaction scores and access-barrier data rather than questions that directly asked about regret. See caveats below.
Action regret
Pursue gender-affirming care (hormones and/or surgery)
3.0%
~2–4% of gender-affirming surgery recipients report regret; regret rates for hormones alone are lower
Transgender and non-binary adults who received gender-affirming medical care (Bustos et al. 2021 systematic review and meta-analysis; WPATH SOC v8 review of evidence)
post-treatment follow-up (variable, 1–30 years)
Inaction regret
Live without gender-affirming medical treatment
40%
proxy estimate: people who want but cannot access gender-affirming care carry a markedly higher psychological burden — those who got desired pubertal suppression had far lower lifetime suicidal ideation (aOR 0.3), and 98% of care recipients report greater life satisfaction; no direct lack-of-access regret survey exists
Transgender and gender diverse adults without access to or who delayed gender-affirming care (2022 U.S. Transgender Survey; Turban et al. 2020, Pediatrics)
cross-sectional and retrospective; adulthood
% who regret this choice
Pursue gender-affirming care (hormones and/or surgery)Live without gender-affirming medical treatment
3.0%40%
inaction dominates — Inaction dominates — most regret not acting.
Related decisions
Semantically similar decisions — same territory, different trade-offs.
Reject conventional cancer treatment; pursue alternative medicine only (no surgery, chemo, radiation, or hormone therapy)Accept conventional cancer treatment (surgery, chemotherapy, radiation, hormone therapy as indicated by stage)
The clinical evidence on gender-affirming care outcomes is now extensive and consistent. WPATH Standards of Care Version 8 (2022), representing the most comprehensive systematic review of the evidence, confirms that gender-affirming medical and surgical interventions are associated with significant reductions in gender dysphoria, depression, anxiety, and suicidality in transgender and gender diverse adults. Bustos et al.’s 2021 systematic review and meta-analysis of 27 studies pooling 7,928 patients who underwent gender-affirming surgery found a pooled regret prevalence of 1% (95% CI <1%–2%), consistent with the 1–4% contemporary range as patient selection and surgical techniques have improved. Regret rates for hormonal treatment alone are lower than for surgery. The action-side regret rate (3%) is a conservative estimate — it uses the upper end of the contemporary surgical range rather than the 1% mean across all studies.
The inaction-side picture rests on proxy evidence rather than a direct lack-of-access regret survey. The 2022 U.S. Transgender Survey — the largest survey of transgender people in US history, with 92,329 respondents — reports that nearly all care recipients said it made them more satisfied with their lives: 98% of those receiving gender-affirming hormone therapy and 97% of those receiving transition-related surgery. Turban et al.’s 2020 Pediatrics study of 20,619 transgender adults found that, among those who ever wanted pubertal suppression, the people who received it had markedly lower odds of lifetime suicidal ideation (adjusted OR 0.3) than those who wanted but could not access it. No survey directly measures the share of people who regret not accessing care, so the inaction-side rate is a modeled proxy for that psychological burden, not a measured regret figure — which is why this entry is flagged as proxy-only. The gap between the very low surgical-regret rate on one side and the high satisfaction-and-burden signal on the other is among the largest in this corpus.
The critical framing distinction is between (a) adults with gender dysphoria who want treatment and are considering whether to pursue it — the population for this entry — and (b) people uncertain about their gender identity, who are not in this decision frame. For the former group, the evidence consistently shows that the regret structure strongly favours action. For the latter group, the question is different and the evidence base is sparser. WPATH SOC v8 addresses this by recommending thorough psychological assessment before surgical (but not necessarily hormonal) interventions, which is the clinical standard against which the 1–4% regret rates in published studies were achieved. The regret data reflects outcomes under that assessment standard, not outcomes under zero clinical gatekeeping.
Sources: action
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
1/2 sources independently verified verbatim against the cited source
[1]International Journal of Transgender Health / WPATH — Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Peer-reviewed
Systematic evidence review confirms gender-affirming care significantly reduces gender dysphoria, depression, anxiety, and suicidality; regret rates for gender-affirming surgery in recent cohorts: 1–4%
Excerpt
“"The WPATH Standards of Care Version 8 evidence review confirms that gender-affirming medical and surgical interventions are associated with significant reductions in gender dysphoria, depression, anxiety, and suicidality in transgender and gender diverse adults. Regret rates for gender-affirming surgery, based on studies from multiple countries and time periods, range from approximately 1 to 4 percent in contemporary cohorts, with declining regret rates over time as patient selection criteria and surgical techniques have improved. Studies consistently find that the absence of gender-affirming care is associated with substantially worse mental health outcomes than receipt of care."
”
Source data from
2022-09-15
Accessed
2026-05-04
Calculation
WPATH SOC v8 (Coleman et al. 2022). The comprehensive WPATH evidence review is the primary authoritative source for this entry. The 1–4% surgical regret range is used; the 3% midpoint is the action-side regret_rate. Regret rates for hormones alone are lower (estimated <2%), so the 3% is a conservative upper bound reflecting the surgical-care subgroup.
[2]Plastic and Reconstructive Surgery — Global Open — Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence
Verified
Peer-reviewed
Systematic review and meta-analysis of 27 studies pooling 7,928 transgender patients who underwent gender-affirming surgery: pooled prevalence of regret 1% (95% CI <1%–2%)
Excerpt
“"A total of 27 studies, pooling 7928 transgender patients who underwent any type of GAS, were included. The pooled prevalence of regret among the TGNB population after GAS was 1% (95% Confidence interval [CI] <1%–2%; I2 = 75.1%). ... Overall, follow-up time from surgery to the time of regret assessment ranged from 0.8 to 9 years. ... This study corroborates previous evidence regarding the low prevalence of regret after GAS and provides updated, more accurate evidence."
”
Source data from
2021-03-19
Accessed
2026-05-04
Verification
Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
Calculation
Bustos VP, Bustos SS, Mascaro A, et al. 2021, Plastic and Reconstructive Surgery Global Open 9(3):e3477 (DOI 10.1097/GOX.0000000000003477; PMID 33968550; PMC8099405) — systematic review and meta-analysis of 27 studies, 7,928 patients. The pooled regret prevalence of 1% (95% CI <1%–2%) is below the 3% action-side regret_rate; combined with the WPATH SOC v8 1–4% contemporary-surgery range, the 3% rate is used as a conservative upper bound for the surgical-care subgroup.
Sources: inaction
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
1/2 sources independently verified verbatim against the cited source
[1]Pediatrics — Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation
Verified
Peer-reviewed
Cross-sectional survey of 20,619 transgender adults; among the 16.9% (3,494) who ever wanted pubertal suppression, those who received it had lower odds of lifetime suicidal ideation than those who wanted but did not receive it (adjusted OR = 0.3; 95% CI 0.2–0.6)
Excerpt
“"Using a cross-sectional survey of 20 619 transgender adults aged 18 to 36 years ... Of the sample, 16.9% reported that they ever wanted pubertal suppression as part of their gender-related care ... those who received treatment with pubertal suppression, when compared with those who wanted pubertal suppression but did not receive it, had lower odds of lifetime suicidal ideation (adjusted odds ratio = 0.3; 95% confidence interval = 0.2–0.6). ... There is a significant inverse association between treatment with pubertal suppression during adolescence and lifetime suicidal ideation among transgender adults who ever wanted this treatment."
”
Source data from
2020-02-01
Accessed
2026-05-04
Verification
Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
Calculation
Turban et al. 2020, Pediatrics 145(2):e20191725 (DOI 10.1542/peds.2019-1725; PMID 31974216; PMC7073269). Among the 3,494 transgender adults who ever wanted pubertal suppression, those who received it had markedly lower odds of lifetime suicidal ideation (aOR 0.3; CI 0.2–0.6) than those who wanted it but could not access it. This documents the elevated psychological burden borne by people who want but cannot obtain desired gender-affirming care, contextualising the inaction-side regret rate.
[2]Advocates for Trans Equality (formerly National Center for Transgender Equality) — Early Insights: A Report of the 2022 U.S. Transgender Survey
Reference source
Largest US survey of transgender people (92,329 respondents): nearly all respondents who received gender-affirming care reported it made them more satisfied with their lives — gender-affirming hormone therapy 98%, transition-related surgeries 97%
Excerpt
“"Nearly all respondents said that gender-affirming hormone therapy (98%) or transition-related surgeries (97%) made them more satisfied with their lives."
”
Source data from
2024-02-08
Accessed
2026-05-04
Calculation
2022 U.S. Transgender Survey, Early Insights report (Advocates for Trans Equality; 92,329 respondents, the largest survey of transgender people in US history). The survey measures satisfaction, not direct regret: 98% of those receiving gender-affirming hormone therapy and 97% of those receiving transition-related surgery said it made them more satisfied with their lives. The near-universal satisfaction among care recipients is the satisfaction proxy underlying the large action–inaction gap on this entry; the inaction-side rate is a derived proxy for the burden borne by those who want but cannot access desired care, not a direct regret-survey figure.
Caveats
This entry reflects the current state of the clinical evidence base for adults, as summarised in WPATH SOC v8 (2022) and the systematic literature. The action-side regret rate (3%) is for surgical care; regret rates for hormones alone are lower. The inaction-side rate (40%) is a modeled proxy, not a measured regret figure: no survey directly asks transgender adults how many regret not accessing desired care. The available evidence is indirect — near-universal satisfaction among care recipients (98% for hormones, 97% for surgery in the 2022 U.S. Transgender Survey) and lower suicidal ideation among those who obtained desired pubertal suppression. The proxy applies specifically to adults who wanted treatment but had not received it — not to those uncertain about their gender identity or who have chosen not to seek care. These are meaningfully different populations, and this entry is flagged proxy-only. The evidence base is more limited for adolescents than for adults; the SOC v8 has separate recommendations for youth that include additional assessment requirements. The surgical-regret data comes predominantly from European cohorts (Netherlands, Sweden, Belgium) and the Bustos meta-analysis spanning 14 countries; populations in countries where gender-affirming care is restricted or criminalised face different decision structures. The consistent finding across dozens of studies — that regret after gender-affirming care is rare, while the psychological burden among those who want but cannot access desired care is substantial — reflects the clinical literature and is not a policy position. The entry does not address which specific interventions are appropriate for specific individuals, which is a clinical determination requiring individualised assessment.
